LINC01436: A Potential Drug Target and Biomarker (G100996609)

Target Name: LINC01436

NCBI ID: G100996609

LINC01436

Other Name(s): long intergenic non-protein coding RNA 1436 | Long intergenic non-protein coding RNA 1436

LINC01436: A Potential Drug Target and Biomarker

LINC01436 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell-cycle and is involved in the development, maintenance, and progression of various diseases, including cancer. LINC01436 is also known as HDAC11 and has been shown to play a critical role in the regulation of cell growth, apoptosis, and autophagy.

The discovery of LINC01436 as a potential drug target and biomarker has significant implications for the development of new treatments for various diseases. By targeting LINC01436, researchers can potentially inhibit its activity and reduce the growth and progression of cancer cells. Additionally, LINC01436 has also been shown to be involved in the regulation of cellular processes that are important for the development and maintenance of neurodegenerative diseases, such as Alzheimer's and Parkinson's.

LINC01436 is a member of the heat shock protein (HSP) family, which are proteins that are involved in the regulation of various cellular processes, including stress response, protein folding, and intracellular signaling. HSPs are highly conserved across various species and are known to play a critical role in the regulation of cellular processes that are essential for the survival and proper function of cells.

LINC01436 is expressed in a wide range of tissues and cells and has been shown to play a role in the regulation of various cellular processes, including the cell cycle, apoptosis, and autophagy. It is a key regulator of the G1/S checkpoint, which is a critical checkpoint that ensures that cells divide and grow in a controlled manner. LINC01436 has been shown to regulate the activity of the G1 checkpoint kinase, which is involved in the regulation of the G1/S checkpoint.

In addition to its role in the cell cycle, LINC01436 is also involved in the regulation of apoptosis, which is the process by which cells undergo programmed cell death. LINC01436 has been shown to play a role in the regulation of apoptosis by regulating the activity of the executor of apoptosis, which is a protein that is involved in the execution of programmed cell death.

LINC01436 is also involved in the regulation of autophagy, which is the process by which cells break down and recycle their own damaged or unnecessary components. Autophagy is a critical process for the survival and proper function of cells and LINC01436 has been shown to play a role in its regulation.

The potential drug target and biomarker status of LINC01436 makes it an attractive target for researchers to study and develop new treatments for various diseases. By inhibiting LINC01436's activity, researchers can potentially reduce the growth and progression of cancer cells and improve the treatment outcomes for neurodegenerative diseases. Additionally, the identification of LINC01436 as a potential drug target and biomarker has significant implications for the development of new therapies for various diseases, including cancer, neurodegenerative diseases, and respiratory diseases.

In conclusion, LINC01436 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its role in the regulation of the cell cycle, apoptosis, and autophagy makes it an attractive target for researchers to study and develop new treatments for various diseases. Further research is needed to fully understand the potential of LINC01436 as a drug target and biomarker and to develop effective treatments for the various diseases it is involved in.

Protein Name: Long Intergenic Non-protein Coding RNA 1436

The "LINC01436 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01436 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets